2013
DOI: 10.1073/pnas.1216011110
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of pathogenic human monoclonal autoantibodies against GM-CSF

Abstract: The origin of pathogenic autoantibodies remains unknown. Idiopathic pulmonary alveolar proteinosis is caused by autoantibodies against granulocyte–macrophage colony-stimulating factor (GM-CSF). We generated 19 monoclonal autoantibodies against GM-CSF from six patients with idiopathic pulmonary alveolar proteinosis. The autoantibodies used multiple V genes, excluding preferred V-gene use as an etiology, and targeted at least four nonoverlapping epitopes on GM-CSF, suggesting that GM-CSF is driving the autoantib… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
30
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 39 publications
(31 citation statements)
references
References 58 publications
1
30
0
Order By: Relevance
“…Secondary PAP develops in association with functional impairment or reduced number of alveolar macrophages such as due to some hematologic cancers, inhalation of inorganic dusts or toxic fumes and pharmacologic immunosuppression [51]. While idiopathic PAP was eventually identified as an autoimmune disease caused by GM-CSF autoantibodies [5153], the primary stimulus leading to the production of GM-CSF autoantibodies remains unknown [54,55]. To advance the understanding of PAP pathogenesis, exogenous GM-CSF was administered to patients with acquired PAP, which appeared to benefit patients with therapeutic efficacy [56,57].…”
Section: Gm-csf Neutralizing Antibody and Susceptibility To Cryptomentioning
confidence: 99%
“…Secondary PAP develops in association with functional impairment or reduced number of alveolar macrophages such as due to some hematologic cancers, inhalation of inorganic dusts or toxic fumes and pharmacologic immunosuppression [51]. While idiopathic PAP was eventually identified as an autoimmune disease caused by GM-CSF autoantibodies [5153], the primary stimulus leading to the production of GM-CSF autoantibodies remains unknown [54,55]. To advance the understanding of PAP pathogenesis, exogenous GM-CSF was administered to patients with acquired PAP, which appeared to benefit patients with therapeutic efficacy [56,57].…”
Section: Gm-csf Neutralizing Antibody and Susceptibility To Cryptomentioning
confidence: 99%
“…Formal testing of this hypothesis may be significant for human disease as well. To-date, no studies have examined the importance of Tfh cells, CD275-CD278 interactions, and/or IL-21 in human disease, though GM-CSF-specific autoantibodies from aPAP patients are heavily somatically hypermutated 16 suggesting a role for Tfh cells.…”
Section: Discussionmentioning
confidence: 99%
“…aPAP patients treated with rituximab, a B cell depleting anti-CD20 monoclonal antibody, exhibit improvement in lipid homeostasis and overall outcome, illustrating that B cells and antibody are necessary for the pathology 13-15 . GM-CSF-specific autoantibodies in aPAP patients are polyclonal and somatically hypermutated IgG antibodies 16, 17 . Interestingly, GM-CSF-specific IgG autoantibodies are also detectable in healthy individuals, though titers are significantly lower compared to aPAP patients 18 .…”
Section: Introductionmentioning
confidence: 99%
“…It is supposed to account for more than 90% of all human PAP diseases. A series of GM-CSF neutralizing autoantibodies have been recently characterized (Wang et al 2013). Particle exposure is generally not considered to be a cause.…”
Section: Introductionmentioning
confidence: 99%